A practical reference on actin binding: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-06-02 and is reviewed periodically as new material appears.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized solid as supplied |
| Water solubility | Soluble | Dissolves in aqueous media |
| Typical storage temperature | -20 °C | Dry powder, desiccated, protected from light |
| Typical analytical method | RP-HPLC with mass spectrometry | Purity from peak area; mass for identity |
| Common synonyms | Tβ4 fragment; thymosin beta-4 fragment | Naming varies by supplier and catalogue |
TB-500 is a synthetic peptide whose sequence corresponds to a short fragment near the N-terminus of thymosin beta-4, a small protein present in most mammalian cells. The fragment is commonly cited as containing the actin-binding region of the parent molecule, which is why it appears in laboratory work on cell migration and tissue repair. Suppliers distribute it as a lyophilised powder intended for research use. Its identity is defined by amino acid sequence and by the presence of an acetyl group on the N-terminal residue.
Full-length thymosin beta-4 consists of roughly forty-three amino acids and ranks among the more abundant small proteins in the cytoplasm. The fragment is much shorter, so it cannot reproduce every function attributed to the intact molecule. In cell culture, short actin-binding motifs can interfere with filament dynamics and cell movement, but such observations come from controlled experiments rather than from whole-animal work. Whether a truncated fragment produces the same effects as the parent protein remains an open question.
Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.
Published research on the intact protein is substantial, covering actin regulation, cell migration, and wound models. Research using the heptapeptide fragment specifically is far smaller, and much of the circulating material originates in supplier documentation rather than peer-reviewed reports. Where fragment studies do exist, they often employ different sequences, chain lengths, or terminal modifications, which complicates direct comparison across papers. Readers encountering claims about TB-500 should therefore separate evidence about thymosin beta-4 from evidence about the fragment itself.
Discussion of the compound frequently appears alongside other short peptides described as fragments of larger proteins. That grouping is convenient but can be misleading, because fragment length, charge, and modification state determine how a peptide behaves in solution and in any experimental system. A seven-residue acetylated peptide and a full-length protein differ in mass by roughly an order of magnitude, and they cannot be assumed to share distribution or binding properties. Precision about which molecule is under discussion is the single most useful step when reading such material.
The regulatory position is broadly consistent across major jurisdictions: no thymosin beta-4 fragment is an approved medicine, and laboratory material is commonly labelled as not intended for human consumption. Anti-doping rules in sport list thymosin beta-4 and its fragments among prohibited peptide hormones. Because these products travel through research-chemical channels rather than pharmaceutical supply chains, quality varies considerably between vendors. Independent testing of identity, purity and sterility is the only dependable check, and a certificate of analysis describes one batch rather than a supplier's whole catalogue.
Lyophilized peptide powder is normally held desiccated at −20 °C, with −80 °C used for longer storage periods. Allowing a sealed vial to reach room temperature before opening is standard practice, because condensation forming on cold powder introduces moisture. Once dissolved, solutions are typically kept cold and shielded from light. Repeated freeze-thaw cycles are avoided because they encourage aggregation and gradual loss of material. These conventions are general to synthetic peptides rather than unique to any one sequence.
Purity and identity are separate measurements and are often confused. Reverse-phase high-performance liquid chromatography, usually with ultraviolet detection near 214 nanometres, reports the share of total peak area belonging to the target compound. Mass spectrometry by electrospray or matrix-assisted laser desorption then checks whether the observed mass matches the expected sequence. Neither measurement alone shows that a vial holds the intended peptide. Peptide content, meaning the fraction of vial mass that is genuine peptide rather than counter-ion, water or residual acid, is reported separately and is frequently lower than the stated purity figure.
These studies have produced models of protein adhesive and other biopolymer deteriorations and the concurrent pore system development. The reduction in bodily repair capability during aging is important to studies of senescence and age-associated disease, and allows the determination of age in living animals. Forensic science can use this technique to estimate the age of a cadaver or an objet d'art to determine authenticity.
Xi has ruled out a multi-party system for China, saying that "constitutional monarchy, imperial restoration, parliamentarism, a multi-party system and a presidential system, we considered them, tried them, but none worked." However, Xi considers China to be a democracy, saying that "China's socialist democracy is the most comprehensive, genuine and effective democracy." China's definition of democracy is different from liberal democracies and is rooted in Marxism–Leninism, and is based on the phrases people's democratic dictatorship and democratic centralism. Xi has additionally coined the term whole-process people's democracy which he said was about having "the people as masters". Foreign analysts and observers have widely disputed that China is a democracy, saying that it is a one-party authoritarian state and Xi an authoritarian leader. Xi has sometimes referred to as "traditionalist" or "neo-authoritarian". Xi has additionally rejected Westernisation as the only way to modernize, instead promoting what he says is Chinese modernization.
Caldwell Dyson was assigned for her second space flight on November 21, 2008. Her second space mission consisted of a six-month trip to the International Space Station. Caldwell Dyson successfully lifted off on April 2, 2010, from the Baikonur spaceport on board the Soyuz TMA-18 as Flight Engineer 2 with Soyuz Commander Aleksandr Skvortsov and Flight Engineer 1 Mikhail Korniyenko. Following a two-day rendezvous and docking maneuver with the ISS, she joined Expedition 23 as a flight engineer and transferred on June 2, 2010, to Expedition 24 again as a flight engineer after the departure of the Soyuz TMA-17. During the first half of her flight, Caldwell Dyson and the Expedition 23 crew were joined by the STS-131 crew from April 7 to April 17. This period was the first and only time that four women were together on board the same spacecraft: Caldwell Dyson, NASA astronauts Stephanie Wilson and Dorothy Metcalf-Lindenburger, and JAXA astronaut Naoko Yamazaki. From May 16 to May 23, the second and last Space Shuttle visiting mission for Caldwell-Dyson's flight, STS-132, joined the Expedition 23 crew for the installation of the Russian-built module Rassvet. The second half of Caldwell Dyson's mission was marked by the failure of a coolant pump at the beginning of August. Caldwell Dyson performed her first spacewalk on August 7, 2010, with NASA astronaut Douglas Wheelock. The task for this first of three contingency EVAs was to prepare the malfunctioning coolant pump for replacement on the next spacewalks; this took place on August 11, 2010, and August 16, 2010.
Sources: en.wikipedia.org
C.; Schwab, M.; Viegas, M. H.; Roseboom, T. J. (2015). "Prenatal Undernutrition and Leukocyte Telomere Length in Late Adulthood". The American Journal of Clinical Nutrition. 102 (3): 655–660. doi:10.3945/ajcn.115.112326. PMID 26178721. S2CID 4493294. Chen, R.; et al. (2012). "Personal Omics Profiling Reveals Dynamic Molecular and Medical Phenotypes". Cell. 148 (6): 1293–1507. doi:10.1016/j.cell.2012.02.009. PMC 3341616. PMID 22424236. Bernardes De Jesus, B.; Schneeberger, K.; Vera, E.; Tejera, A.; Harley, C. B.; Blasco, M. A. (2011). "The Telomerase Activator TA-65". Aging Cell. 10 (4): 604–621. doi:10.1111/j.1474-9726.2011.00700.x. PMC 3627294. PMID 21426483.
=== Surface modification === Surface cleaning and pretreatment for large area deposition Thin film deposition Deposition of thick diamond-like carbon (DLC) films Surface roughening of polymers for improved adhesion and/or biocompatibility
Commission B2: Refrigerating Equipment Commission B2 Refrigerating Equipment participates in many IIR activities aimed at promoting knowledge of refrigeration technologies and their applications worldwide. It is a key Commission for most IIR activities, synergising with other Commissions. The Commission is very active in various IIR Working Groups on Magnetic Cooling and Refrigeration Safety.
Sources: en.wikipedia.org
TB-500 is a name used for a short synthetic peptide fragment taken from the actin-binding region of thymosin beta-4. Material sold under this label is usually a lyophilized powder supplied for laboratory research rather than a licensed medicine. The commonly cited sequence is LKKTETQ.
The parent protein contains forty-three amino acids, while the fragment carries only a short motif from one region. The fragment can interact with actin in vitro, but it does not include the rest of the protein structure. Whether the shorter molecule behaves the same way in living systems is not settled.
Published controlled human studies are scarce, and most activity reports come from cell culture or animal models. Reviews often describe the evidence base as limited and methodologically uneven. Open questions include the relationship between route, dose, and measured outcomes.
No. Thymosin beta-4 is a 43-residue protein, while TB-500 refers to a seven-residue fragment corresponding to its N-terminal region. The two names are often used loosely in commercial and community writing, which obscures the difference in size, sequence, and likely behavior.